Table 2.
Hazard Ratios (95% Confidence Intervals)a for Incident Cardiovascular Disease Comparing SGLT2 Inhibitor Users vs. Users of Other 2nd Line Therapies, MarketScan Databases, 2013–2019
| SGLT2 Inhibitor Users (n=53,691) | Other 2nd Line Therapy Users (n=259,705) | |
|---|---|---|
|
|
||
| Composite CVD Outcome | ||
| N, events | 1,178 | 8,609 |
| Incidence Rateb | 12.07 | 18.83 |
| Hazard Ratio (95% CI) | 0.66 (0.62, 0.71) | Reference |
| Stroke | ||
| N, events | 210 | 1,934 |
| Incidence Rateb | 2.15 | 4.23 |
| Hazard Ratio (95% CI) | 0.52 (0.45, 0.60) | Reference |
| Atrial Fibrillation | ||
| N, events | 653 | 4,060 |
| Incidence Rateb | 6.69 | 8.88 |
| Hazard Ratio (95% CI) | 0.79 (0.73, 0.86) | Reference |
| Myocardial Infarction | ||
| N, events | 313 | 2,311 |
| Incidence Rateb | 3.21 | 5.06 |
| Hazard Ratio (95% CI) | 0.65 (0.58, 0.73) | Reference |
| Heart Failure | ||
| N, events | 112 | 1,287 |
| Incidence Rateb | 1.15 | 2.82 |
| Hazard Ratio (95% CI) | 0.45 (0.37, 0.54) | Reference |
a
Adjusted for age, sex, ICD-9/10 status, propensity score (hypertension, kidney disease, chronic pulmonary disease, depression, metastatic cancer, asthma, ACE inhibitors, alpha-blockers, angiotensin receptor blockers, beta-blockers, calcium channel blockers, loop diuretics, potassium-sparing diuretics, thiazide diuretics, direct vasodilators)
b
Per 1,000 person-years
Abbreviations: SGLT2 = sodium-glucose cotransporter-2